Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -45.98% | 107.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.17% | 83.26% | |||
| Operating Income | 31.17% | -83.26% | |||
| Income Before Tax | 37.40% | -93.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.40% | -93.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.40% | -93.75% | |||
| EBIT | 31.17% | -83.26% | |||
| EBITDA | 31.21% | -83.85% | |||
| EPS Basic | 45.58% | -90.58% | |||
| Normalized Basic EPS | 45.63% | -90.64% | |||
| EPS Diluted | 45.58% | -90.58% | |||
| Normalized Diluted EPS | 45.63% | -90.64% | |||
| Average Basic Shares Outstanding | 15.13% | 1.59% | |||
| Average Diluted Shares Outstanding | 15.13% | 1.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||